Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Boston Scientific ( (BSX) ) has provided an update.
On November 18, 2025, Boston Scientific‘s Board of Directors approved the 2026 Annual Bonus Plan and two performance share programs, aiming to align executive compensation with company performance and shareholder interests. The bonus plan and performance share programs, effective from January 1, 2026, to December 31, 2028, are designed to incentivize employees based on company-wide metrics such as global sales, earnings, and sustainability goals, with potential impacts on executive compensation through policies like the Dodd-Frank Clawback Policy.
The most recent analyst rating on (BSX) stock is a Buy with a $132.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.
Boston Scientific’s overall stock score is driven by strong financial performance and positive earnings call outcomes. While the technical analysis and valuation present some concerns, the company’s robust growth trajectory and raised guidance support a favorable outlook.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
Boston Scientific Corporation operates in the medical device industry, providing a range of products and services focused on medical solutions. The company is known for its innovative approaches in healthcare, particularly in the development and manufacturing of medical devices that improve patient care and outcomes.
Average Trading Volume: 8,978,845
Technical Sentiment Signal: Buy
Current Market Cap: $150.9B
Find detailed analytics on BSX stock on TipRanks’ Stock Analysis page.